Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
ATHLONE, Ireland, Sept. 07, 2016 -- Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical and medical device company with late stage development programs targeting areas of significant unmet medical need, today announced that Anthony Zook, Chief Executive Officer of Innocoll Holdings plc, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016, at 11:10 a.m. ET at the Grand Hyatt Hotel in New York, NY.
About Innocoll Holdings plc
Innocoll is a global, specialty pharmaceutical company with late stage development programs that is dedicated to engineering better medicines to help patients get better. Our proprietary, biocompatible, and biodegradable collagen products are precision-engineered for targeted use. Applied locally to wound and/or surgery sites, they are designed to provide a range of benefits. The company's late stage product pipeline is focused on addressing a number of large unmet medical needs, including: XARACOLL for the treatment of postoperative pain; COGENZIA (INL-002), a gentamicin-collagen topical matrix for the adjuvant treatment of diabetic foot infections; and COLLAGUARD (INL-003), a barrier for the prevention of post-surgical adhesions.
Our currently approved products include: COLLAGUARD® (ex-US), COLLATAMP® G, SEPTOCOLL® E, REGENEPRO®, COLLACARE®, COLLEXA®, and ZORPREVA®.
Corporate: Pepe Carmona Chief Financial Officer (215) 983-3362 [email protected] Jeannie Sorenson, M.D. Vice President, Investor Relations (314) 458-7355 [email protected]
